22.01.2024 07:16:02

Sandoz To Acquire CIMERLI Business From Coherus - Quick Facts

(RTTNews) - Sandoz has signed an agreement to acquire the US biosimilar ranibizumab CIMERLI from Coherus BioSciences, Inc. for an upfront cash purchase payment of $170 million. The company said the agreement allows it to build a more robust ophthalmic platform that would support future product launches. The company noted that CIMERLI is interchangeable with LUCENTIS for all approved indications.

Keren Haruvi, President Sandoz North America, said: "The addition of CIMERLI reinforces our commitment to biosimilars and represents a huge step towards our goal of pioneering patient access to more affordable and much-needed medicines in the US."

For More Such Health News, visit rttnews.com.

Analysen zu Coherus BioSciences Incmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Coherus BioSciences Inc 1,52 5,60% Coherus BioSciences Inc
Sandoz Group AG (spons. ADRs) 39,20 -1,51% Sandoz Group AG (spons. ADRs)